Physician
Radiology
Dr. Paul A. Lyle, MD
|
|
Give Review
Paul Lyle works in the field of Radiology. He graduated from University of Minnesota Medical School. University of Minnesota Medical School is ranked 40/10 in Research/PrimaryCare. Paul Lyle is a published physician. He has 34 publications published. The most current publication "Comparing hypertension guidelines. Guidelines are based on evidence from trials, not normal practice." He accepts Medicare payments and is registered with Medicare.gov.
Publications
- Comparing hypertension guidelines. Guidelines are based on evidence from trials, not normal practice.
- A multicenter, randomized, double-blind, placebo-controlled, 8-week trial of the efficacy and tolerability of once-daily losartan 100 mg/hydrochlorothiazide 25 mg and ...
- Clusters of metabolic risk factors predict cardiovascular events in hypertension with target-organ damage: the LIFE study.
- First-dose effects of enalapril 2.5 mg and captopril 6.25 mg in patients with heart failure: a double-blind, randomized, multicenter study. The Enalapril-Captopril Inv...
- The effect of losartan compared with atenolol on the incidence of revascularization in patients with hypertension and electrocardiographic left ventricular hypertrophy...
- A double-blind, randomized study evaluating losartan potassium monotherapy or in combination with hydrochlorothiazide versus placebo in obese patients with hypertension.
- The effect of losartan on hemoglobin concentration and renal outcome in diabetic nephropathy of type 2 diabetes.
- The effect of baseline physical activity on cardiovascular outcomes and new-onset diabetes in patients treated for hypertension and left ventricular hypertrophy: the L...
- Effects of losartan in women with hypertension and left ventricular hypertrophy: results from the Losartan Intervention for Endpoint Reduction in Hypertension Study.
- ACE gene polymorphism and losartan treatment in type 2 diabetic patients with nephropathy.
- Effect of ACE insertion/deletion and 12 other polymorphisms on clinical outcomes and response to treatment in the LIFE study.
- Predictors of cardiovascular events in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention for Endpoint reduction in hypertension st...
- Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction i...
- The left atrium, atrial fibrillation, and the risk of stroke in hypertensive patients with left ventricular hypertrophy.
- Effect of LDL cholesterol and treatment with losartan on end-stage renal disease in the RENAAL study.
- Effect of hemoglobin levels on cardiovascular outcomes in patients with isolated systolic hypertension and left ventricular hypertrophy (from the LIFE study).
- Fixed combination of losartan and hydrochlorothiazide and reduction of risk of stroke.
- Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL study.
- Atenolol as a comparator in outcome trials in hypertension: a correct choice in the past, but not for the future?
- A multicenter, randomized, double-blind, parallel-group trial of the antihypertensive efficacy and tolerability of a combination of once-daily losartan 100 mg/hydrochl...
- Use of beta-blockers, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers to prevent atrial fibrillation.
- Losartan: lessons learned from the RENAAL study.
- Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? ...
- Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies.
- Targeting the renin-angiotensin system for the reduction of cardiovascular outcomes in hypertension: angiotensin-converting enzyme inhibitors and angiotensin receptor ...
- Kidney disease and cardiovascular disease: implications of dyslipidemia.
- Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophy.
- The effects of losartan compared to atenolol on stroke in patients with isolated systolic hypertension and left ventricular hypertrophy. The LIFE study.
- Losartan for the treatment of hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
- Losartan and the United States costs of end-stage renal disease by baseline albuminuria in patients with type 2 diabetes and nephropathy.
- Hypertension and medical informatics.
- An analysis of cholesterol control and statin use in the Losartan Intervention for Endpoint Reduction in Hypertension Study.
- Recent advances in management of type 2 diabetes and nephropathy: lessons from the RENAAL study.
Schools
Univ Of Mn Med Sch
Mayo Grad School MedMayo Fndn
Doctors Specialties
- Diagnostic Radiology
- Radiology
Accepted Insurances
- Choice Plus POS II
- Blue Card PPO
- Blue Cross Blue Shield of Illinois PPO
- Blue Care Network PCP Focus Network
- Group Employees PPO
- Great West Healthcare-Cigna PPO
- Cofinity PPO
- Choice Plus POS
- Navigate POS
- Options PPO
Education
-
Mayo School of Graduate Medical Education -
University of Minnesota Medical School
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1427131093 |
| Last Name Of The Provider | LYLE |
| First Name Of The Provider | PAUL |
| View All |
Similar Doctors
|
|
Dr. Ethelbert M. Lara, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Aaron S. Tragos, DO |
|
|
Dr. Nathan D. McParlan, MD
This Doctor is OpenDoctor Recommended.
|